Sinovac Biotech, Ltd
SVA
SVA was delisted on the 22nd of February, 2019.
9 hedge funds and large institutions have $418M invested in Sinovac Biotech, Ltd in 2024 Q3 according to their latest regulatory filings, with 1 funds opening new positions, 1 increasing their positions, 0 reducing their positions, and 17 closing their positions.
0% more funds holding in top 10
Funds holding in top 10: 3 → 3 (0)
0% less capital invested
Capital invested by funds: $420M → $418M (-$1.19M)
65% less funds holding
Funds holding: 26 → 9 (-17)
94% less first-time investments, than exits
New positions opened: 1 | Existing positions closed: 17
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
-$849K |
| 2 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$106K |
| 3 |
Geode Capital Management
Boston,
Massachusetts
|
-$89.7K |
| 4 |
Wells Fargo
San Francisco,
California
|
-$80.6K |
| 5 |
Morgan Stanley
New York
|
-$50.6K |
SVA Hedge Fund Activity: Q3 2024 in Review
9 of the 6,978 institutional investors tracked by Wall St. Rank reported a position in Sinovac Biotech, Ltd (SVA) for Q3 2024, worth a combined $418M — down 0.28% from $420M a quarter earlier.
Sellers outnumbered buyers: 17 funds closed out of SVA and 1 opened new positions — a net loss of 16 holders — while 0 trimmed existing stakes and 1 added.
The largest seller was Renaissance Technologies, exiting entirely with an estimated $849K sold.
- 9 institutional investors held Sinovac Biotech, Ltd (SVA) as of Q3 2024, down from 26 in Q2 2024.
- Funds reported $418M of Sinovac Biotech, Ltd stock for Q3 2024, down 0.28% quarter-over-quarter.
- 1 fund opened new Sinovac Biotech, Ltd positions in Q3 2024 and 17 closed out, a net change of -16 holders.
- The largest Sinovac Biotech, Ltd seller in Q3 2024 was Renaissance Technologies, an estimated $849K sold.
Based on aggregated 13F filings for Q3 2024.